Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS
- 187 Downloads
Mephedrone is a synthetic cathinone consumed as a recreational drug. Recently, it was identified several of its metabolites in vivo in humans but there is little information about its pharmacokinetics in plasma and urine. Although several analytical methods have been proposed for mephedrone quantification in different matrices, none are available for its metabolites. Therefore, the aim of the study was to develop and validate an analytical method using liquid chromatography-tandem mass spectrometry for the quantification of mephedrone, nor-mephedrone, N-succinyl-nor-mephedrone, 1′-dihydro-mephedrone, and 4′-carboxy-mephedrone. The method was validated in human plasma and urine and in rat brain homogenates. Six healthy male subjects, recreational users of new psychoactive substances, ingested 150 mg of mephedrone within the context of a clinical trial. 4′-Carboxy-mephedrone, followed by nor-mephedrone, was the most abundant metabolites found in plasma. Dihydro-mephedrone represented 10% of the amount of mephedrone in plasma and N-succinyl-nor-mephedrone was the metabolite eliminated with the longer half-life of 8.2 h. In urine, 4′-carboxy-mephedrone was the main metabolite excreted with amounts recovered being about 10 times those of mephedrone. Additionally, the validated method was used to test metabolite ability to cross the blood-brain barrier in vivo in rats with mephedrone and nor-mephedrone as the main active compounds present in the brain. The method described is useful for the determinations of mephedrone and metabolites in biological samples.
KEY WORDSanalytical method LC-MS/MS mephedrone nor-mephedrone pharmacokinetics
- 2.European Monitoring Centre for Drugs and Drug Addiction. Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. 2011. p.1–193.Google Scholar
- 3.United Nations Office on Drugs and Crime. World Drug Report. New York; 2016. p.1–174.Google Scholar
- 6.Hong W, Ko Y, Lin M, Wang P, Chen Y, Chiueh L, et al. Determination of synthetic cathinones in urine using gas chromatography–mass spectrometry techniques. J Anal Toxicol. 2016;40(1):12–6.Google Scholar
- 7.Olesti E, Pujadas M, Papaseit E, Pérez-Mañá C, Pozo ÓJ, Farré M, et al. GC–MS quantification method for mephedrone in plasma and urine: application to human pharmacokinetics. J Anal Toxicol [Internet]. 2016;2–8. Available from: http://jat.oxfordjournals.org/lookup/doi/10.1093/jat/bkw120.
- 8.Torrance H, Cooper G. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int [Internet]. 2010;202(1–3):e62–3. doi:10.1016/j.forsciint.2010.07.014.
- 9.Mercolini L, Protti M, Catapano MC, Rudge J, Sberna AE LC-MS/MS and volumetric absorptive microsampling for quantitative bioanalysis of cathinone analogues in dried urine, plasma and oral fluid samples. J Pharm Biomed Anal. 2016;123:186–94.Google Scholar
- 12.Shah SAB, NIK D, Barker J, Petróczi A, Cross P, Archer R, et al. Quantitative analysis of mephedrone using liquid chromatography tandem mass spectroscopy: application to human hair. J Pharm Biomed Anal. 2012;61:64–9.Google Scholar
- 15.Pozo ÓJ, Ibáñez M, Sancho JV, Lahoz-beneytez J, Farré M, Papaseit E, et al. Mass spectrometric evaluation of mephedrone in vivo human metabolism: identification of phase I and phase II metabolites, including a novel succinyl conjugate s. Drug Metab Dispos. 2014;43:248–57.CrossRefPubMedGoogle Scholar
- 17.Khreit OIG, Grant MH, Zhang T, Henderson C, Watson DG, Sutcliffe OB. Elucidation of the phase I and phase II metabolic pathways of (±)-4′-methylmethcathinone (4-MMC) and (±)-4′-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS2. J Pharm Biomed Anal. 2013;72:177–85.Google Scholar
- 18.Meyer MR, Wilhelm J, Peters FT, Maurer HH. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2010;397(3):1225–33.CrossRefPubMedGoogle Scholar
- 20.Critical Review Report of Mephedrone. Expert Committe on Drug Dependence, World Health Organisation. 2014.Google Scholar
- 21.Papaseit E, Pérez-Mañá C, Mateus J-A, Pujadas M, Fonseca F, Torrens M, et al. Human pharmacology of mephedrone in comparison to MDMA. Neuropsychopharmacology. 2016;41(11):2704–13.Google Scholar
- 22.Mayer FP, Wimmer L, Dillon-Carter O, Partilla JS, Burchardt N, Mihovilovic MD, et al. Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. Br J Pharmacol. 2016;173(17):2657–68.Google Scholar
- 23.Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol. 2012;22(3):231–6.Google Scholar
- 25.European Medicines Agency. Guideline on bioanalytical method validation. EMA Guidel [Internet]. 2012;44(July 2011):1–23. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500109686&mid=WC0b01ac058009a3dc Google Scholar
- 26.Deventer K, Pozo OJ, Verstraete AG, Van Eenoo P. Dilute-and-shoot-liquid chromatography-mass spectrometry for urine analysis in doping control and analytical toxicology. TrAC - Trends Anal Chem. 2014;55:1–13.Google Scholar
- 28.de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA. Ther Drug Monit [Internet]. 2004;26(2):137–44.Google Scholar
- 33.Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology [Internet]. 2012;37(5):1192–203. Nature Publishing Group; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3306880&tool=pmcentrez&rendertype=abstract CrossRefGoogle Scholar